RESUMEN
Background: intensive physical activity is known to induce oxidative stress. that could endanger the health of athletes. Also Quercetin is a flavonoid with antioxidant and anti-inflammatory properties
Objective: the aim of this study was to investigate the effect of quercetin on time to exhaustion and oxidative stress in male soccer players
Methods: this placebo?controlled, double?blind clinical trial was conducted on 22 football players for Six weeks. The subjects were randomly assigned to one of two groups to receive quercetin [1000 mg] or placebo [1000 mg dextrose]. Anthropometric measurements, time to exhaustion and blood biochemical parameters including SOD, CAT, GPx and MDA were measured at the beginning and end of the study and the data were analyzed using paired t-test
Results: at the end of the study in Quercetin group time to exhaustion, Enzyme activity of SOD, CAT and GPx were significantly increased [P<0.05] and mean serum malondialdehyde [MDA] were significantly decreased [P<0.05]. Also mean of these parameters between the two groups were significantly different from each other [P <0.5]
Conclusion: in this study, supplementation with 1000 mg of Quercetin per day for 6 weeks, increased time to exhaustion and SOD, CAT and GPx enzyme activity and decreased serum malondialdehyde significantly
RESUMEN
To compare the efficacy of intravitreal clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis. In this prospective, randomized single-masked clinical trial a total of 68 patients with active ocular toxoplasmosis were assigned randomly to 2 treatment groups: 34 in the intravitreal clindamycin plus dexamethasone [IVCD] group and 34 in the classic treatment [CT] group. The IVCD group received 1 to 3 injection[s] of 1 mg intravitreal clindamycin and 400 microg dexamethasone, and the CT group received 6 weeks of treatment with pyrimethamine and sulfadiazine plus prednisolone. Antitoxoplasmosis antibodies [immunoglobulin [Ig] M and IgG] were measured using an enzyme-linked immunosorbent assay. The mean number of injections in the IVCD group was 1.6. Lesion size reduction was statistically significant after treatment in both IVCD and CT groups [P< 0.001 and P: 0.009, respectiveiy]. The difference in mean percentage of reduction at 6 weeks was not significant: 57 +/- 27.6% in the IVCD group versus 58.4 +/- 29.3% in the CT group. In comparison to baseline, VA increased by 0.44 +/- 0.24 and 0.29 +/- 0.19 logarithm of the minimum angle of resolution units in the IVCD and CT groups, respectively [P< 0.001]; however, the difference in VA improvement between the groups was not significant. The interaction effect of IgM and treatment group on lesion size reduction was significant [P= 0.002]; this indicated that IgM-positive cases responded better to CT and IgM-negative cases responded better to IVCD treatment. Vitreous inflammation reduction was comparable between the groups. Within 2 years, 4 eyes [2 in each group] had 1 episode of recurrence. Adverse drug reactions occurred in 2 patients in the CT group. No major injection-related complication was encountered in the IVCD group. Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to classic treatment in ocular toxoplasmosis. It may offer more convenience, a safer systemic profile, greater availability, and fewer follow-up visits and hematologic evaluations
RESUMEN
To compare the anatomical results of scleral buckling surgery with and without retinopexy in the management of phakic rhegmatogenous retinal detachment [RD]. In this retrospective, nonrandomized, interventional, comparative case series, data of 71 phakic eyes of 71 patients with rhegmatogenous RD that had undergone scleral buckling were evaluated. The procedure in 41 consecutive eyes was accompanied by retinopexy using intraoperative transscleral cryotherapy [6 cases] or postoperative laser photocoagulation [35 cases].The next 30 eyes did not receive retinopexy.The primary outcome measure was retinal redetachment rate.The secondary outcomes measures were final visual acuity and the occurrence of cystoid macular edema and macular pucker. The two groups were matched regarding age, sex, history of trauma or high myopia, and duration of RD before the surgery as well as the characteristics of the breaks and RD except for RD externt which was more in the non-retinopexy group. Retinal redetachment occurred in 4 patients [13.3%] in the nonretinopexy group and in 6 patients [14.6%] in the retinopexy group.The difference was not statistically significant [P>0.999].Neither was the difference between the groups significant in terms of final visual acuity and the occurrence of cystoid macular edema and macular pucker. Retinopexy does not seem to offer additional benefit to scleral buckling surgery for phakic rhegmatogenous RD in terms of anatomical and functional success. However, thses findings have to be confirmed in a randomized clinical trial
RESUMEN
To compare the visual outcomes of four different therapeutic modalities for central retinal vein occlusion [CRVO] with each other and with the natural course of the disease. This study was conducted on 63 eyes of 63 patients including 13 eyes in the radial optic neurotomy [RON] group, 10 eyes in the combined RON and intraocular triamcinolone injection [RON/IOT] group, 12 eyes in the combined internal limiting membrane peeling, RON and IOT [ILMP/RON/IOT] group, 14 eyes in the intravitreal triamcinolone injection [IVT] group and 14 untreated control eyes. All patients were followed for six months. Final best-corrected visual acuity [BCVA] was better in the IVT group as compared to the RON [P=0.037], RON/IOT [P=0.401], ILMP/RON/IOT [P=0.023] and control [P=0.025] groups. However, after adjusting final BCVA for baseline BCVA, only the RON/IOT group showed significant visual improvement after 1 [P= 0.025], 3 [P= 0.023] and 6 [P= 0.054] months as compared to controls. Among the four different approaches evaluated in this study, RON/IOT may entail better visual outcomes in the management of CRVO within six months
RESUMEN
To evaluate the effect of intravitreal triamcinolone acetonide [IVT] reinjection on clinical and optical coherence tomographic [OCT] features in refractory diabetic macular edema [DME]. In an interventional case series, all IVT-treated patients enrolled in a previous clinical trial [45 subjects], were recalled for performing a new ophthalmologic examination and OCT. Suitable eyes for reinjection received 4 mg IVT. Complete ophthalmologic examination and OCT were performed after two and four months.From 45 recalled patients, 23 were included for the new study [51.1% response rate]. Of these, only 12 cases were considered as candidates for reinjection. Visual acuity [VA] changes were not significant in the reinjected eyes after both the first and the second interventions, although there was a relative improvement [0.14 logMAR] at two months after the first injection. Central macular thickness [CMT] was reduced by 27 and 49 pt two and four months after the reinjection and 43 and 40.t at two and four months after the first injection. None of the mentioned changes was significant. I013 elevation was significant two and four months after the second injection [3.6 and 2.4 mmHg, respectively, P<0.05]. However, it was significant [5.58 mmHg, P=0.001] only two months after the first injection. The transient beneficial effects of IVT on refractory DME are not repeated with second injections. However, IVT-related ocular hypertension is more persistent after reinjection
RESUMEN
To evaluate the influence of different confounding factors on the effect of intravitreal triamcinolone acetonide injection for refractory diabetic macular edema. In a prospective placebo-controlled randomized clinical trial, 88 eyes with refractory diabetic macular edema were randomly assigned into two groups including 45 in the treatment group [4 mg intravitreal triamcinolone acetonide] and 43 in the placebo group. Multivariate analysis was performed for three main outcomes, including visual acuity, central macular thickness, and the amount of hard exudates. Confounding factors that showed some effect on the main outcomes were used for building multivariate models. It was revealed that blood urea nitrogen, fasting blood sugar, serum cholesterol, initial visual acuity, presence of cystoid macular edema, amount of hard exudates, and size of foveal avascular zone had some influence on visual acuity outcome; previous macular photocoagulation, serum cholesterol, baseline central macular thickness, initial intraocular pressure, amount of hard exudates, and size of foveal avascular zone had some influence on visual acuity outcome; previous macular photocoagulation, serum cholesterol, baseline central macular thickness, initial intraocular pressure, amount of hard exudates, and size of foveal avascular zone had some influence on central macular thickness changes; and serum cholesterol, baseline central macular thickness, and amount of hard exudates had some influence on hard exudates in both groups. Size of foveal avascular zone, initial intraocular pressure, amount of hard exudates, and baseline central macular thickness also had an additive effect on the outcomes in the treatment group. Many confounding factors may influence the effect of intravitreal triamcinolone. These factors should be considered when adopting intravitreal triamcinolone. These factors should be considered when adopting intravitreal triamcinolone as a treatment strategy for refractory diabetic macular edema
RESUMEN
To evaluate the effect of oral prednisolone on visual outcome and complications of scleral buckling [SB] in patients with rhegmatogenous retinal detachment [RRD]. In a randomized double-blind placebo-controlled trial, patients with acute RRD who underwent SB were randomly divided into two groups. Oral prednisolone was administered for the treatment group and placebo for the control group. The two groups were compared for visual acuity [VA] , retinal detachment [RD], cystoid macular edema [CME], and proliferative vitreoretinopathy [PVR]. The trial was performed on 25 patients in the treatment group and 27 patients in the placebo group. Mean preoperative VA [LogMAR] was 1.46 +/- 0.81 overall, including 0.85 +/- 0.62 in location were equal in both group. [P=0.45] Significant PVR was seen in one eye in the treatment group and 3 eyes in the placebo group. [P=0.39]. Postoperative oral prednisolone does not seem to affect visual outcomes and complications of scleral buckling in phakic patients